ICG-001 is primarily used in research settings to study the Wnt/β-catenin signaling pathway, which plays a critical role in cell proliferation, differentiation, and tissue regeneration. It acts as a selective inhibitor of this pathway by disrupting the interaction between β-catenin and its transcriptional coactivator CBP. This makes it a valuable tool in understanding the molecular mechanisms underlying various diseases, particularly cancer, where aberrant Wnt signaling is often implicated. Researchers also explore its potential in regenerative medicine, as modulating this pathway could influence tissue repair and stem cell behavior. Additionally, ICG-001 has been investigated for its therapeutic potential in conditions like fibrosis and inflammatory diseases, where Wnt signaling contributes to pathological processes. Its application remains largely experimental, with ongoing studies aimed at uncovering its full therapeutic potential.